ADDED
Broadridge Broadridge Corporate Issuer Solutions, LLC BVF Biotechnology Value Fund, L.P.
Cash-Out Agreement Cash-Out Agreement between the Company and Thomas M.
Burns dated October 22, 2025 cGMP current Good Manufacturing Practice Company XOMA Royalty Corporation (formerly XOMA Corporation), including its subsidiaries DoD U.S.
Food and Drug Administration FDCA The Federal Food, Drug, and Cosmetic Act, as amended FDIC Federal Deposit Insurance Corporation GAAP Generally accepted accounting principles G A General and administrative HCRP Healthcare Royalty Partners II, L.P.
Wainwright Co., LLC IP Intellectual Property IPR D In-Process Research and Development IRA Inflation Reduction Act Leerink Leerink Partners LLC MAA Marketing Authorization Application NDA New Drug Application NOL Net operating loss PSU Performance stock unit R D Research and development Regeneron Regeneron Pharmaceuticals, Inc.
Amended Retention Plan October 25, 2022 amendment to the Retention Plan Retention Plan Retention and Severance Plan dated March 31, 2022 RSU Restricted stock unit SAB No.
99 Topic 1.M., Materiality SAB No.108, Topic 1.N Staff Accounting Bulletin No.
108, Considering the Effects of Misstatements when Quantifying Misstatements in the Current Year Financial Statements SEC U.S.
United States XOMA XOMA Royalty Corporation (formerly XOMA Corporation), a Nevada corporation, including its subsidiaries XRL XRL 1 LLC, a wholly-owned subsidiary of the Company Royalty and Commercial Payment Purchase Agreements: AAA Assignment and Assumption Agreement Affitech Affitech Research AS Affitech CPPA The Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021 Agenus Agenus, Inc.
Aronora RPA The Company's Royalty Purchase Agreement with Aronora dated April 7, 2019 Bioasis Bioasis Technologies, Inc.
REMOVED
Riley dated August 5, 2021 40 Act Investment Company Act of 1940 AAA Assignment and Assumption Agreement ACA The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 Affitech Affitech Research AS Affitech CPPA The Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021 Agenus Agenus, Inc.
and certain affiliates Agenus RPA The Company's Royalty Purchase Agreement with Agenus dated September 20, 2018 Alora Alora Pharmaceuticals Alexion Alexion Pharmaceuticals Alexion License Agreement Exclusive License Agreement between the Company and Alexion (formerly Amolyt Pharma SAS, Amolyt ) dated December 19, 2024 Aptevo Aptevo Therapeutics Inc.
cGMP current Good Manufacturing Practice Chiesi Chiesi Farmaceutici S.p.A.
Company XOMA Royalty Corporation (formerly XOMA Corporation), including its subsidiaries CPPA Commercial Payment Purchase Agreement CVR Contingent value right Dar Organon License Agreement Exclusive License Agreement between Dar and Organon, dated March 31, 2022, as amended July 4, 2023 Dar RPAs The Company s Traditional Royalty Purchase Agreement and Synthetic Royalty Purchase Agreement, both with Dar dated April 29, 2024 Day One Day One Biopharmaceuticals, Inc.
Department of Defense EC European Commission EIR Effective interest rate EMA European Medicines Agency ESPP 2015 Employee Stock Purchase Plan, as amended EU European Union Exchange Act U.S.
Food and Drug Administration FDCA The Federal Food, Drug, and Cosmetic Act, as amended Fortis Fortis Advisors LLC, representative of the Kinnate CVR holders under the Kinnate CVR Agreement GAAP Generally accepted accounting principles G A General and administrative Gossamer Bio Gossamer Bio, Inc.
(formerly NantCell, Inc.) ImmunityBio License Agreement Out-license agreement to ImmunityBio from LadRx dated July 27, 2017, related to the development and commercialization of Aldoxorubicin, as amended on September 27, 2018 IP Intellectual Property IPR D In-Process Research and Development IXINITY coagulation factor IX (recombinant) Janssen Janssen Biotech, Inc.
Merck Merck Sharp Dohme Corp Merck KGaA Ares Trading SA Merck KGaA License Agreement In-license agreement from Merck KGaA to ObsEva related to ebopiprant dated June 10, 2015 and subsequently amended on July 8, 2016 (assumed by the Company as part of the ObsEva IP Acquisition Agreement) MIPLYFFA arimoclomol NDA New Drug Application NOL Net operating loss Novartis Novartis Pharma AG, Novartis International Pharmaceutical Ltd., Novartis Institutes for Biomedical Research, Inc.
ObsEva ObsEva SA ObsEva IP Acquisition Agreement Company's IP Acquisition Agreement with ObsEva dated November 21, 2022 OJEMDA tovorafenib Ology Bioservices Ology Bioservices Inc.
(formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.) Organon Organon International GmbH Organon License Agreement Out-license agreement to Organon from ObsEva dated July 26, 2021, related to the development and commercialization of ebopiprant (assumed by the Company as part of the ObsEva IP Acquisition Agreement) OVAPRENE An investigational hormone-free monthly intravaginal contraceptive Palo Palobiofarma, S.L.